KR20240128852A - 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 - Google Patents
암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 Download PDFInfo
- Publication number
- KR20240128852A KR20240128852A KR1020247021664A KR20247021664A KR20240128852A KR 20240128852 A KR20240128852 A KR 20240128852A KR 1020247021664 A KR1020247021664 A KR 1020247021664A KR 20247021664 A KR20247021664 A KR 20247021664A KR 20240128852 A KR20240128852 A KR 20240128852A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- alkyl
- cancer
- kras
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284778P | 2021-12-01 | 2021-12-01 | |
| US202163284754P | 2021-12-01 | 2021-12-01 | |
| US63/284,754 | 2021-12-01 | ||
| US63/284,778 | 2021-12-01 | ||
| PCT/EP2022/083954 WO2023099624A1 (en) | 2021-12-01 | 2022-11-30 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240128852A true KR20240128852A (ko) | 2024-08-27 |
Family
ID=84536046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247021664A Pending KR20240128852A (ko) | 2021-12-01 | 2022-11-30 | 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
Country Status (17)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| CN120265617A (zh) | 2022-11-30 | 2025-07-04 | 勃林格殷格翰国际有限公司 | 制备螺环kras抑制剂的方法及中间体 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| US20250019385A1 (en) * | 2023-05-30 | 2025-01-16 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2024255795A1 (en) * | 2023-06-14 | 2024-12-19 | Insilico Medicine Ip Limited | Kras inhibitors and uses thereof |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| KR20260054710A (ko) | 2023-08-17 | 2026-04-22 | 트리라인 바이오사이언시스, 인크. | 스피로시클릭 디히드로피라노피리미딘 KRas 저해제 |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| CN117946135A (zh) * | 2024-01-24 | 2024-04-30 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025190158A1 (zh) * | 2024-03-14 | 2025-09-18 | 四川科伦博泰生物医药股份有限公司 | 螺环化合物、其制备方法及用途 |
| WO2025190342A1 (zh) * | 2024-03-15 | 2025-09-18 | 苏州浦合医药科技有限公司 | 螺环化合物作为kras突变体抑制剂 |
| WO2025201480A1 (zh) * | 2024-03-28 | 2025-10-02 | 苏州浦合医药科技有限公司 | 螺环化合物作为kras突变体抑制剂 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202606711A (zh) * | 2024-06-19 | 2026-02-16 | 香港商英矽智能科技知識產權有限公司 | 作為kras抑制劑的新化合物及其用途 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026007740A1 (zh) * | 2024-07-04 | 2026-01-08 | 四川科伦博泰生物医药股份有限公司 | 螺环化合物、其制备方法及用途 |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119330881A (zh) * | 2024-09-06 | 2025-01-21 | 苏州汉德创宏生化科技有限公司 | 一种3-氨甲基-1-h吡唑的合成方法 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026114957A1 (en) | 2024-11-27 | 2026-06-04 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| US20260146049A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2026114918A1 (en) | 2024-11-27 | 2026-06-04 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32317A (es) | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| MA37405A1 (fr) | 2012-03-14 | 2016-03-31 | Lupin Ltd | Composés hétérocyclyle |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| JP6577958B2 (ja) | 2014-04-11 | 2019-09-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン誘導体およびMDM2−p53阻害剤としてのそれらの使用 |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| JP6591532B2 (ja) | 2014-08-21 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | MDM2−p53阻害剤としての新しいスピロ[3H−インドール−3,2’−ピロリジン]−2(1H)−オン化合物および誘導体 |
| HUE054985T2 (hu) | 2015-10-09 | 2021-11-29 | Boehringer Ingelheim Int | Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok |
| ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| MX2019006299A (es) | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas. |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CA3056970A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| US11186554B2 (en) | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| PL3728254T3 (pl) | 2017-12-21 | 2023-06-12 | Boehringer Ingelheim International Gmbh | Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1 |
| EP3781565A1 (en) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| BR112021001709A2 (pt) * | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| CA3141604A1 (en) | 2019-05-20 | 2020-11-26 | 1200 Pharma Llc | Kras g12c inhibitors and uses thereof |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CR20220258A (es) * | 2019-12-11 | 2022-07-03 | Lilly Co Eli | Inhibidores de kras g12c |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2021139748A1 (en) | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| TWI894229B (zh) | 2020-03-16 | 2025-08-21 | 瑞士商諾華公司 | 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物 |
| CN113683616B (zh) | 2020-05-18 | 2025-12-30 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| CN116034106B (zh) | 2020-06-02 | 2025-11-04 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441051A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| US20230227470A1 (en) * | 2021-12-01 | 2023-07-20 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| TW202340209A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
-
2022
- 2022-11-30 CR CR20240233A patent/CR20240233A/es unknown
- 2022-11-30 MX MX2024006681A patent/MX2024006681A/es unknown
- 2022-11-30 PE PE2024001288A patent/PE20241356A1/es unknown
- 2022-11-30 AU AU2022402390A patent/AU2022402390A1/en active Pending
- 2022-11-30 WO PCT/EP2022/083954 patent/WO2023099624A1/en not_active Ceased
- 2022-11-30 JP JP2024532457A patent/JP2024543967A/ja active Pending
- 2022-11-30 EP EP22823522.2A patent/EP4441055A1/en active Pending
- 2022-11-30 KR KR1020247021664A patent/KR20240128852A/ko active Pending
- 2022-11-30 CN CN202411691317.4A patent/CN119841847A/zh active Pending
- 2022-11-30 IL IL312905A patent/IL312905A/en unknown
- 2022-11-30 CA CA3240980A patent/CA3240980A1/en active Pending
- 2022-11-30 TW TW111145888A patent/TW202337431A/zh unknown
-
2023
- 2023-05-09 US US18/314,445 patent/US12060367B2/en active Active
-
2024
- 2024-05-24 DO DO2024000101A patent/DOP2024000101A/es unknown
- 2024-05-30 CL CL2024001617A patent/CL2024001617A1/es unknown
- 2024-05-30 JO JOJO/P/2024/0124A patent/JOP20240124A1/ar unknown
- 2024-05-31 CO CONC2024/0007014A patent/CO2024007014A2/es unknown
- 2024-06-26 US US18/755,002 patent/US20250002504A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023099624A1 (en) | 2023-06-08 |
| US12060367B2 (en) | 2024-08-13 |
| CL2024001617A1 (es) | 2024-12-20 |
| EP4441055A1 (en) | 2024-10-09 |
| CR20240233A (es) | 2024-07-17 |
| MX2024006681A (es) | 2024-08-26 |
| CO2024007014A2 (es) | 2024-07-29 |
| CA3240980A1 (en) | 2023-06-08 |
| DOP2024000101A (es) | 2024-08-15 |
| CN119841847A (zh) | 2025-04-18 |
| US20250002504A1 (en) | 2025-01-02 |
| AU2022402390A1 (en) | 2024-05-30 |
| US20240174690A1 (en) | 2024-05-30 |
| TW202337431A (zh) | 2023-10-01 |
| JP2024543967A (ja) | 2024-11-26 |
| PE20241356A1 (es) | 2024-07-03 |
| IL312905A (en) | 2024-07-01 |
| JOP20240124A1 (ar) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7808056B2 (ja) | がんを治療するための縮合環化2-アミノ-3-シアノチオフェン及び誘導体 | |
| EP4441055A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| KR102746913B1 (ko) | Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체 | |
| JP2024543975A (ja) | 癌の処置のための環化2-アミノ-3-シアノチオフェン及び誘導体 | |
| WO2023099608A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| WO2024246099A1 (en) | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| JP2024543976A (ja) | 癌の処置のための環化2-アミノ-3-シアノチオフェン及び誘導体 | |
| CN118647620A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| HK40097417A (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240628 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |